Sign in
CompletedPhase 1

A study to characterize the pharmacokinetic profile of norucholic acid (NCA) in patients with primary sclerosing cholangitis (PSC)

Key facts

Who runs it
Dr. Falk Pharma GmbH
Where
Austria, Finland, Germany, and Norway10 sites in 4 countriesChoose a country to see its sites
Status
Completed
Phase
Phase 1
People taking part
33 people enrolled
Started
20 Jul 2023
Ended
29 Nov 2024
Type of study
Interventional
Record updated
15 September 2024

Who can take part

Age
18 years and older
Sex
Women and men
Healthy volunteers
Cannot take part

This trial has no sites in United States.

It has sites in 4 countries. Choose a country to see its sites.

Data and sources

Registry record
Listed on the EU's official list of trials (CTIS).How to verify a trial in the registry
Record updated
15 September 2024